Leading Manufacturer of Balloon-Expandable Valves Launches Self-Expanding Device

Edwards Lifesciences could have been satisfied after the success of the PARTNER trials and the improvements to its balloon-expandable valve (mainly as regards the delivery system profile and paravalvular leak reduction) in its last model, SAPIEN 3. However, it was not. The company decided to keep going, developing a valve that is radically different from its traditional product. That new valve is CENTERA, a nitinol self-expanding device with a low-profile delivery system (14 Fr) that is motorized, for better implant control!

La empresa líder en válvulas balón expandibles lanza también su válvula autoexpandible

The system also allows for device repositioning. The only thing in common with Sapien 3 is that both valves are made of bovine pericardium.


Read also: Mild Leaks: TAVR’s Silent Enemies”.


Between 2015 and 2016, 203 patients with severe aortic stenosis and high surgical risk treated by transfemoral access were analyzed. The mean age for this population was 82.7 ± 5.5 years old.

 

At 30 days, mortality was 1%, disabling stroke occurred in 2.5% of patients, and New York Heart Association functional class I/II was observed in 93.0% of all cases. Effective orifice area increased from 0.71 ± 0.20 cm² to 1.88 ± 0.43 cm² (p < 0.001) and the mean gradient decreased from 40.5 ± 13.2 mm Hg to 7.2 ± 2.8 mm Hg at 30 days post-procedure (p < 0.001).


Read also: Who Lives Longer After TAVR, Men or Women?”


Paravalvular aortic regurgitation at 30 days was moderate or higher in 0.6% of patients and 4.5% of patients required a new pacemaker.

 

Conclusion

This work confirms the safety and efficacy of the new Edwards device, highlighting its very low rates of new pacemaker implantation, probably the lowest ever for a self-expanding valve.

 

Original title: Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients with Severe Aortic Stenosis.

Reference: Hermann Reichenspurner et al. J Am Coll Cardiol 2017;70:3127-36.


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...